For $700M+, Vi­a­tris nabs two biotechs as eye dis­ease em­pha­sis comes in­to view

Vi­a­tris is con­tin­u­ing its plot to shift strate­gies, an­nounc­ing two ac­qui­si­tions Mon­day morn­ing in the wake of a re­port to sell off its Eu­ro­pean con­sumer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER